Special Issue "Chronic Viral Infections and Cancer, Openings for Therapies and Vaccines"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".

Deadline for manuscript submissions: 10 July 2022 | Viewed by 338

Special Issue Editors

Dr. Maria G. Isaguliants
E-Mail Website
Guest Editor
1. Kirchenstein Institute of Microbiology and Virology, Riga Stradins University, Ratsupites 5, LV-1069 Riga, Latvia
2. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobelsvägen 16, 17177 Stockholm, Sweden
Interests: virus; immunology; microbiology; immunity; ELISA; cell culture; immunology of infectious diseases; flow cytometry; infection; HIV
Special Issues, Collections and Topics in MDPI journals
Dr. Alexander Ivanov
E-Mail Website
Guest Editor
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
Interests: polyamines; urea cycle; proline metabolism; reactive oxygen species; S-glutathionylation; hepatitis C virus; hepatitis delta virus
Special Issues, Collections and Topics in MDPI journals
Dr. Franco M. Buonaguro
E-Mail Website
Guest Editor
Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy
Interests: oncology; molecular biology; virology; biochemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Approximately one out of eight human cancers has a viral etiology. Viral cancers open unique opportunities for prophylaxis, diagnosis, and therapy, as demonstrated by the success of HBV and HPV vaccines, as well as HCV antivirals in decreasing the incidence of tumors associated with these infections.

For other chronic viral infections and associated cancers, problems still dominate over progress. Prophylactic HPV vaccination does not cure already established infections, although an adjuvant role has been identified following conventional treatment, urgently requesting development of therapeutic HPV vaccines. Several are in the pipeline, but still far from actual application for treatment of HPV-related cancers. Development of HCV vaccines is in progress but hampered by HCV variability and absence of longitudinal sterilizing antiviral response. The success of antiretroviral therapy in controlling HIV-1 replication and immune reconstitution did not lead to significant reduction in HIV-1 associated cancers, indicating alternative mechanisms of their development not connected to immune suppression, requiring in-depth study and clinical interventions.

In this Special Issue, we aim to unravel the progress in the studies of the molecular pathogenesis of chronic viral infections and cover the common mechanisms of action of human oncogenic viruses, such as the activity of viral oncoproteins, the induction of genomic instability, the support of chronic inflammation, and the modulation of tumor microenvironment. Special attention will be devoted to virus-induced alterations in the functions of the immune system, to induction of innate and adaptive immune responses, including the relationship between immune response and viral infections, metabolism, and immunometabolism, as well as to oncolytic viruses. In-depth understanding of these processes would create new openings for the design of novel viral vaccines and immunotherapies.

A special invitation to submit is addressed to the participants of the international symposium “Chronic Viral Infections and Cancer, Openings for Vaccines” held online on 16–17 December 2021 www.techvac.org, sponsored by Cancers

Dr. Maria G. Isaguliants
Dr. Alexander Ivanov
Dr. Franco M. Buonaguro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • chronic viral infection
  • high-risk human papillomaviruses
  • Epstein–Barr virus
  • human hepatitis C virus
  • human hepatitis B virus
  • human hepatitis D virus
  • human immunodeficiency virus type I
  • cancer
  • metastasis
  • oxidative stress
  • metabolism
  • immunometabolism
  • genomic instability
  • DNA damage
  • innate immunity
  • adaptive immunity
  • viral vaccines
  • cancer vaccines
  • adjuvants
  • immunotherapy
  • animal models of chronic viral infections and cancer

Published Papers

This special issue is now open for submission.
Back to TopTop